Ibogaine for Alcohol and Stimulant Addiction: Treatment Protocols and Success Rates
While ibogaine gained recognition primarily for treating opioid addiction, its therapeutic potential extends to other substance dependencies that devastate lives and resist conventional treatment. Alcohol use disorder affects an estimated 29 million Americans (SAMHSA, 2023), and stimulant addiction—particularly cocaine and methamphetamine—has surged alongside the opioid crisis.
Yet effective treatments remain elusive, and relapse after conventional rehabilitation is common for both alcohol and stimulant addictions. Ibogaine offers a fundamentally different approach—resetting the neurobiological systems underlying compulsive substance use.
Understanding the Neurobiology
Alcohol: GABA & Glutamate Dysregulation
Alcohol enhances GABAergic signaling (sedation, anxiety reduction) while inhibiting glutamate. Chronic use causes receptor adaptations that lead to hyperexcitability during withdrawal—tremors, anxiety, seizures, and potentially fatal delirium tremens.
Current treatment gap: Benzodiazepines manage acute withdrawal, but long-term abstinence outcomes after conventional treatment remain poor.
Stimulants: Dopamine System Overdrive
Cocaine blocks dopamine reuptake (3-5x baseline surge). Methamphetamine not only blocks reuptake but causes dopamine to leak from storage vesicles (10x baseline). Chronic use depletes dopamine, downregulates receptors, and can cause neurotoxicity.
Current treatment gap: No FDA-approved medications for stimulant addiction, and relapse within months is very common.
How Ibogaine Works for Non-Opioid Addictions
For Alcohol Addiction
NMDA Receptor Antagonism
Ibogaine is a non-competitive NMDA receptor antagonist. This appears to reverse glutamate system adaptations caused by chronic alcohol use. Animal studies show ibogaine reduces alcohol withdrawal severity and voluntary consumption for weeks after a single dose (Rezvani et al., 1995).
GABA System Modulation
While ibogaine doesn't directly activate GABA receptors, it appears to normalize GABAergic tone through downstream effects. Patients report reduced anxiety and improved sleep weeks after treatment.
Dopamine System Reset
Ibogaine's effects on dopamine signaling—particularly through GDNF upregulation—may help restore reward system sensitivity, reducing the compulsion to drink (He et al., 2005).
For Stimulant Addiction
Dopamine System Repair: The Key Mechanism
Ibogaine increases GDNF production in the brain, promoting repair and regeneration of dopaminergic neurons damaged by chronic stimulant use (Glick et al., 1998). Animal studies show rats dramatically reduce cocaine self-administration for weeks after a single ibogaine treatment.
Research Evidence
Alcohol Research
- 1995 Preclinical (Rezvani et al.): Ibogaine significantly reduced alcohol consumption in alcohol-preferring rats for up to 3 days after single administration.
- 2005–2010 Preclinical (He et al., J Neurosci 2005; Carnicella et al., 2010): Ibogaine and noribogaine reduced alcohol self-administration in rodents via GDNF signaling in the ventral tegmental area
- Open-label trial, University of São Paulo (NCT03380728): small alcohol-dependent cohort, completed per the ClinicalTrials.gov registry — no published human abstinence rate for alcohol exists yet
Cocaine Research
- 1992 Glick et al.: Ibogaine dramatically reduces cocaine-seeking behavior in rats, with effects persisting for days to weeks.
- 2018 Open-Label Study (Mash et al.): 191 patients including cocaine-dependent subjects • reduced drug craving and depressed mood after detoxification
- 2014 Brazil Study (Schenberg et al.): 75 polysubstance patients (72% poly-drug, mostly cocaine/crack) • 61% abstinent at interview • median 5.5 months abstinence after one treatment, 8.4 months with multiple
Treatment Protocols
Pre-Treatment Evaluation
For Alcohol Patients
- • Liver function tests (chronic alcohol causes liver damage)
- • Alcohol withdrawal risk assessment
- • Nutritional status (thiamine deficiency common)
- • Benzodiazepine use assessment (must be tapered)
- • If drinking heavily: 3-5 day medically supervised detox with benzodiazepines before ibogaine
For Stimulant Patients
- • Comprehensive cardiac screening (EKG, echocardiogram)
- • Psychiatric evaluation (high rates of co-occurring disorders)
- • Recent use assessment (abstinent 48-72 hours before treatment)
- • No physical withdrawal syndrome, but 48-72 hour observation for cardiovascular stability
Dosing Strategies
There is no validated ibogaine dose for alcohol or stimulant addiction. Published clinical work in opioid detoxification used around 10 mg/kg of ibogaine hydrochloride (Knuijver et al., 2024); clinic protocols vary and are individualized.
- Alcohol: doses are reduced when liver function is impaired; cirrhosis is a contraindication
- Stimulants: cardiac screening drives the dosing decision — stimulant use itself stresses the heart
- All patients: continuous ECG monitoring and on-site emergency capability regardless of dose
Success Rates: Setting Realistic Expectations
Alcohol Addiction Outcomes
No published human study reports abstinence rates for ibogaine in alcohol use disorder — at any time point. The evidence is preclinical (GDNF-mediated reductions in rodent alcohol intake) plus one small completed open-label trial awaiting publication. Treat any precise alcohol success percentage as unsupported.
Cocaine Addiction Outcomes
The only sizable human dataset is retrospective: among 75 Brazilian polysubstance patients (mostly cocaine/crack), 61% were abstinent at interview, with a median of 5.5 months of abstinence after a single treatment and 8.4 months with multiple treatments (Schenberg et al., 2014). No prospective time-point abstinence rates have been published for cocaine.
Factors Predicting Success
- • Treatment engagement: Active participation in integration therapy + ongoing support
- • Severity of dependence: Severe, long-standing addiction may predict better outcomes (higher motivation)
- • Co-occurring disorders: Well-managed depression/anxiety doesn't worsen outcomes; untreated bipolar/schizophrenia predicts poorer response
- • Social stability: Housing, employment, supportive relationships improve outcomes
Evidence-Based Programs for Alcohol and Stimulant Addiction
Specialized ibogaine clinics treating alcohol and stimulant addiction use comprehensive protocols built around these standards:
- • Supervised detoxification for alcohol patients (on-site, 24/7 medical monitoring)
- • Pharmaceutical-grade ibogaine with precise dosing
- • TA+HCL booster protocol for broader neurochemical coverage
- • Continuous medical monitoring (12-lead cardiac telemetry)
- • Integration-focused aftercare (daily therapy during 7-day stay)
- • Polysubstance specialization (alcohol + cocaine, stimulants + opioids)
- • SSRI compatibility (specialized protocols for patients on antidepressants)